All In Biotech

Drug Trial Radar · NCT00175916

Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

853

Actual

Start

Sep 2005

Primary completion

May 2019

Study completion May 2019

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).

Conditions

  • Epilepsy

Interventions

  • Brivaracetam (ucb 34714)Drug

    10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)Time frame: From Entry Visit until Last Visit (up to 162 months)
  2. Percentage of Participants Who Withdrew Due to an Adverse Event (AE)Time frame: From Entry Visit until Last Visit (up to 162 months)
  3. Percentage of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Entry Visit until Last Visit (up to 162 months)

Locations

153 sites in 26 countries. Site status is shown where the registry gives one.

  • 935

    San Francisco, California

  • 933

    Gainesville, Florida

  • 931

    Charlottesville, Virginia

  • 509

    Graz, Austria

  • 507

    Innsbruck, Austria

  • 510

    Linz, Austria

  • 508

    Vienna, Austria

  • 506

    Bruges, Belgium

  • 513

    Ghent, Belgium

  • 974

    La Louvière, Belgium

  • 505

    Leuven, Belgium

  • 501

    Edegem, Antwerpen, Belgium

  • 515

    Montignies-sur-Sambre, Chaleroi, Belgium

  • 951

    Vancouver, British Columbia, Canada

  • 950

    Montreal, Quebec, Canada

  • 952

    Québec, Quebec, Canada

  • 545

    Beroun, Czechia

  • 543

    Brno, Czechia

  • 544

    Brno, Czechia

  • 546

    České Budějovice, Czechia

  • 519

    Ostrava Trebovice, Czechia

  • 517

    Prague, Czechia

  • 541

    Prague, Czechia

  • 542

    Prague, Czechia

  • 518

    Zlín, Czechia

  • 900

    Helsinki, Finland

  • 581

    Kuopio, Finland

  • 526

    Oulu, Finland

  • 582

    Oulu, Finland

  • 527

    Seinäjoki, Finland

  • 583

    Tampere, Finland

  • 811

    Tampere, Finland

  • 632

    Angers, France

  • 628

    Béthune, France

  • 630

    Dijon, France

  • 624

    Lille, France

  • 625

    Marseille, France

  • 623

    Montpellier, France

  • 635

    Nancy, France

  • 626

    Paris, France

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.